Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
MetaCure USA Inc. was the United States subsidiary of MetaCure Ltd., an Israeli medical device company that focused on developing and commercializing novel treatments for type 2 diabetes. Their flagship product was the TANTALUS system, an implantable gastric stimulator designed to improve glycemic control in diabetic patients. The company aimed to provide a less invasive alternative to bariatric surgery for diabetes management. MetaCure Ltd., including its US operations, ceased active operations and reportedly filed for liquidation around 2015-2016 after facing financial difficulties and challenges in bringing its product to wider market adoption despite initial promising clinical trial results and CE Mark approval.
The Irvine office served as the U.S. operational headquarters, managing clinical trials, regulatory affairs (FDA interactions), marketing, and initial commercialization efforts for the TANTALUS system in North America.
Likely standard office space within a business park common in Irvine, suitable for administrative, research support, and sales operations. Not a manufacturing site.
As a company in the innovative med-tech space, the culture was likely focused on research, development, and bringing a novel solution to a major health issue (diabetes). It probably involved a dynamic, results-oriented environment, typical of venture-backed technology firms.
The Irvine headquarters was crucial for MetaCure's efforts to access the large and lucrative U.S. medical market, navigate the FDA approval process, and establish a commercial presence.
MetaCure's global presence was primarily driven by its headquarters in Israel (MetaCure Ltd.) and its significant operational arm in the United States (MetaCure USA Inc.). The company conducted clinical trials in multiple regions, including Europe and the U.S., to support regulatory approvals and market entry for its TANTALUS diabetes treatment system. Their focus was on key medical device markets before operations ceased.
15 Cromwell (Historical Address)
Irvine
CA
USA
Address: Caesarea Industrial Park (Historical Address)
Served as the central hub for innovation, product design, engineering, and strategic oversight for MetaCure's global activities.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, MetaCure' leadership includes:
MetaCure has been backed by several prominent investors over the years, including:
MetaCure USA Inc. and its parent company MetaCure Ltd. ceased active operations around 2015-2016. Therefore, there have been no executive hires or exits in the last 12 months or in recent years.
Discover the tools MetaCure uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Based on common corporate email patterns for companies of its time and type, MetaCure USA Inc. likely used a standard format involving employee names and the company domain (metacure.com). As the company is no longer operational, these formats are purely historical and any emails sent would not be deliverable.
[first_initial][last]@metacure.com (e.g., jsmith@metacure.com) or [first].[last]@metacure.com (e.g. john.smith@metacure.com)
Format
jsmith@metacure.com
Example
0%
Success rate
Globes English • October 28, 2015
Israeli diabetes treatment technology company MetaCure Ltd. has filed for liquidation. The company, which developed an implant for treating Type 2 diabetes, had raised $70 million from investors including Boston Scientific and Pontifax....more
PR Newswire (via Fierce Biotech) • June 25, 2007
MetaCure Ltd. announced it has received CE Mark approval for its TANTALUS(R) System, an implantable device for the treatment of obese type 2 diabetes patients. This approval allows MetaCure to commercialize the system in the European Union....more
MassDevice • March 19, 2012
MetaCure USA Inc. announced the launch of a U.S. pivotal clinical trial for its Tantalus implantable gastric stimulator designed to treat Type II diabetes. The trial aimed to enroll 278 patients across multiple sites....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including MetaCure, are just a search away.